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ABSTRACT
The intracellular environmental is a hostile one. Free radicals and related oxygen and nitrogen-based oxidizing agents persistently 
pulverize and damage molecules in the vicinity of where they are formed. The mitochondria especially are subjected to frequent 
and abundant oxidative abuse. The carnage that is left in the wake of these oxygen and nitrogen-related reactants is referred to as 
oxidative damage or oxidative stress. When mitochondrial electron transport complex inhibitors are used, e.g., rotenone, 1-methyl-
1-phenyl-1,2,3,6-tetrahydropyridine, 3-nitropropionic acid or cyanide, pandemonium breaks loose within mitochondria as electron 
leakage leads to the generation of massive amounts of free radicals and related toxicants. The resulting oxidative stress initiates a series 
of events that leads to cellular apoptosis. To alleviate mitochondrial destruction and the associated cellular implosion, the cell has at its 
disposal a variety of free radical scavengers and antioxidants. Among these are melatonin and its metabolites. While melatonin stimu-
lates several antioxidative enzymes it, as well as its metabolites (cyclic 3-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykynuramine 
and N1-acetyl-5-methoxykynuramine), likewise effectively neutralize free radicals. The resulting cascade of reactions greatly magnifies 
melatonin’s efficacy in reducing oxidative stress and apoptosis even in the presence of mitochondrial electron transport inhibitors. 
The actions of melatonin at the mitochondrial level are a consequence of melatonin and/or any of its metabolites. Thus, the molecular 
terrorism meted out by reactive oxygen and nitrogen species is held in check by melatonin and its derivatives. 
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Introduction
Melatonin (N-acetyl-5-methoxytryptamine) is an endog-
enously-produced molecule found throughout the animal 
kingdom from unicells to humans (Reiter, 1991a; Hardeland 
and Poeggeler, 2003). It is also present in plants (Hattori et 
al., 1995; Reiter et al., 2007; Kolar and MachacKova, 2005). 
Within multicellular organisms melatonin is generated in a 
wide variety of different tissues, although the pineal gland 
is the best known source of the indoleamine in vertebrates 
(Quay, 1974; Reiter, 1991b). Other major sites of melatonin 
production include the eye (Tosini et al., 2006; Itoh et al., 
2007), brain (Jimenez-Jorge et al., 2007), gut (Bubenik and 
Pang, 2007), bone marrow (Tan et al., 1999a), skin (Slominski 
et al., 2005), immune cells (Carrillo-Vico et al., 2005) and 
others (Stefulj et al., 2001). In mammals, melatonin in the 
blood is primarily derived from the pineal gland (Quay, 
1974; Reiter, 1991a). In the blood, melatonin levels exhibit 
a circadian rhythm with highest concentrations occurring 
during the dark period, coincident with maximal nocturnal 
melatonin production in the pineal gland (Reiter, 1987; 
1991a). A melatonin rhythm similar to that in the blood also 
occurs in the cerebrospinal fluid (Skinner and Malpaux, 
1999), saliva (Laakso et al., 1990) and at least one of its 
metabolites, 6-hydroxymelatonin, in the urine (Cavallo and 
Dolan, 1996).
Light-at-night quickly depresses pineal melatonin pro-
duction via a pathway that involves a unique photopigment, 
melanopsin, in specialized photoreceptive retinal ganglion 
cells in the lateral eyes (Panda et al., 2005). The ability of 
light to inhibit nocturnal melatonin synthesis is both inten-
sity (McIntytre et al., 1989) and wavelength (Brainard et al., 
2001) dependent. As pineal melatonin synthesis falls due to 
nocturnal light exposure, likewise blood melatonin levels 
drop (Reiter, 1991a).
Besides  light-at-night,  a  second  major  feature  that 
reduces melatonin formation is age. In all species examined 
to date, increasing age is associated with a gradual waning of 
the nocturnal melatonin rhythm such that the elderly may 
be almost devoid of this important molecule (Reiter et al., 
1980, 1981; Sack et al., 1986). Given the marked beneficial 
actions of melatonin at the cellular level, particularly in 
mitochondria (Acuna-Castroviejo et al., 2001; Leon et al., 
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2004, 2005), the gradual reduction of melatonin through-
out life may contribute to the persistent accumulation of 
oxidatively-modified molecules and worsening of a number 
of mitochondria-related disorders (Acuna-Castroviejo et al., 
2002; DiMauro and Schon, 2003).
Melatonin is a ubiquitously-acting molecule which can 
function as an autocoid, paracoid, hormone, antioxidant 
and  as  a  tissue  factor  (Tan  et  al.,  2003).  As  such,  this 
indoleamine mediates changes in seasonal reproduction in 
photoperiodic species (Reiter, 1980; Goldman, 1999), influ-
ences retinal physiology (Morgan and Boelan, 1996; Tosini, 
2000), modulates the immune system (Guerrero and Reiter, 
2002; Carrillo-Vico et al., 2006), inhibits the growth of a 
number of cancer cells (Blask et al., 2005; Leon-Blanco et al., 
2003; Sanchez-Barcello et al., 2005), reduces oxidative stress 
(Siu et al., 2006; Maldonado et al., 2007; Jaworek et al., 2005), 
promotes sleep (Zisapel, 2007; Jan et al., 2007) and others.
Mechanistically, melatonin achieves its actions via a 
number of means. Many cells are equipped with membrane 
receptors which allow them to respond to the circadian 
melatonin message (Dubocovich and Markowska, 2005; 
Witt-Enderby et al., 2006). Melatonin binding sites (recep-
tors)  have  also  been  found  in  the  nuclei  of  many  cells 
(Pozo et al., 2003; Coto-Montes et al., 2003). Whereas the 
signal transduction mechanisms involved in the actions of 
melatonin at the level of the membrane receptors have been 
reasonably well defined, information on these processes in 
terms of the nuclear binding sites remain, for the most part, 
enigmatic. Intracellularly, melatonin also binds to calm-
odulin allowing it to regulate several intracellular events, 
e.g., nitric oxide synthase (NOS) activity (Pozo et al., 1997; 
Benitez-King, 2006).
Additionally, melatonin has actions that do not require a 
receptor or formation of a complex with another molecule. 
This receptor-independent action, i.e., radical scavenging, 
only requires that melatonin be in the vicinity of a reac-
tive oxygen or nitrogen specie when it is generated (Reiter, 
1995; Tan et al., 2002; Hardeland et al., 2003a). Given that 
mitochondria are a major site of free radical production, it 
would obviously be advantageous if the concentrations of 
melatonin were also high within mitochondria. Whereas 
some  preliminary  data  suggest  that  this  organelle  may 
contain melatonin concentrations that exceed levels in the 
blood or other portions of the cell (Martin et al., 2000), this 
evidence is certainly not unassailable.
Mitochondria and free radical generation
The inner mitochondrial membrane is unusually rich in 
proteins, half of which are involved in electron transport 
and in oxidative phosphorylation. The electron transport 
chain (ETC) which is coupled to oxidative phosphorylation 
provides cells with their major means of generation of its 
energy requirements (Scheffler, 1999). Up to 95% of the 
ATP produced in aerobic cells is a result of mitochondrial 
oxidative phosphorylation. The activities of the ETC and 
oxidative phosphorylation must remain continuously active 
to ensure mitochondrial and cellular survival.
The  majority  of  molecular  oxygen  (O2)  inhaled  and 
eventually taken up by cells is processed in the mitochon-
drial ETC where it is converted to water following its four 
electron reduction. However, during this reductive process, 
partially reduced species of O2 are also produced including 
reactants that are reduced by one, two or three electrons, 
i.e., the superoxide anion (O2
•–) and hydroxyl radical (•OH) 
and one non-radical product, hydrogen peroxide (H2O2). 
Collectively, these agents are referred to as reactive oxygen 
species (ROS).
Free radicals generally have the capability to pair up their 
unpaired electron by abstracting one from another molecule 
(thereby damaging it). O2
•– is not especially reactive in this 
regard. When formed, O2
•– is usually quickly dismutated to 
H2O2 by cytosolic or mitochondrial superoxide dismutase 
(CuZnSOD and MnSOD), respectively. Since H2O2 is the 
immediate precursor of the highly damaging •OH, it is 
imperative  that  H2O2  be  removed  from  the  intramito-
chondrial environment as quickly as possible. The major 
enzyme that accomplishes this is glutathione peroxidase 
(GPx), which metabolizes H2O2 to water and O2; in this 
process GPx also converts reduced glutathione (GSH) to its 
oxidized metabolite (GSSG). Given the major importance of 
GSH in mitochondrial physiology, it is essential that GSSG 
be reduced back to GSH; this is accomplished by glutathione 
reductase (GRd) (Fernandez-Checa and Kaplowski, 2005).
The removal of H2O2 from the mitochondrial environ-
ment is never complete and, via the Fenton reaction, some 
damaging •OH are always formed. Cellular organelles have 
no enzymatic means to remove •OH so it must either be neu-
tralized by a free radical scavenger or it mutilates a bystander 
molecule. This carnage occurs in the immediate vicinity 
of where the •OH is formed because of its extremely rapid 
reaction rate; the damage is referred to as being site specific.
In addition to ROS, mitochondria also generate reactive 
nitrogen species (RNS); two of these are nitric oxide (NO) 
and the peroxynitrite anion (ONOO–). Mitochondrial NO 
functions as a reversible antagonist of complex IV of the 
ETC by competing with O2 for its binding site. Usually tis-
sue concentrations of NO and O2 are, respectively, in the 
ranges of 100–500 nM and 10–30 µM. In these concentra-
tion ranges, NO causes roughly half maximal inhibition 
of mitochondrial respiration. Thus, NO is a physiological 
regulator of respiration and also of the rate of ATP synthesis 
(Brown, 1992). Elevation of NO levels higher than the con-
centrations mentioned above has the potential of inhibiting 
not only complex IV but also complexes I and III. In this 
eventuality, mitochondrial electron transfer reactions are 
compromised and electron leakage is exaggerated leading 
to increased formation of O2
•– and all down stream oxidants 
(Brown and Borutaite, 2004).
Additionally, NO readily couples with the O2
•– to pro-
duce the non-radical species, the ONOO–, which irrevers-
ibly damages respiratory complexes (Cadenas et al., 1996). 
The toxicity of the ONOO– is probably on a par with that 
of the •OH with the resultant damage potentially causing 
mitochondrial dysfunction and cell death (Brown, 1992).
A specific isoform of nitric oxide synthase (NOS) has been 
proposed to exist in mitochondria (mtNOS) (Ghafourifar 139
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and Cadenas, 2005). This constitutively expressed enzyme 
is believed to derive from a neuronal NOS isoform (Tatoyan 
and  Giulivi,  1998).  NO  produced  within  mitochondria 
under normal conditions may serve a regulatory purpose, 
but when generated in excess, such as during inflammation 
(Escames et al., 2006), it may inhibit respiration and ATP 
production. Melatonin has been shown to inhibit NOS 
(Leon et al., 2004; 2005; Maldonado et al., 2007).
Melatonin as a free radical scavenger 
and as an antioxidant
Melatonin was discovered to be a free radical scavenger in 
1993 (Tan et al., 1993). In this capacity, it is unexpectedly 
highly effective. Using the most definitive means of iden-
tifying a scavenger, i.e., a spin trapping agent and electron 
spin resonance spectroscopy, melatonin was documented 
to be a potent scavenger of the devastatingly reactive •OH. 
This seminal observation has been repeatedly confirmed in 
pure chemical systems in both in vitro and in vivo studies 
(Matuszek et al., 1997; Bromme et al., 2000; Li et al., 2002; 
Sofic et al., 2005; Valko et al., 2005; Fukutomi et al., 2006). 
Invariably, the degree of molecular damage that occurs as a 
consequence of •OH generation is reduced in the presence 
of melatonin. This is obvious in the indoleamine’s ability 
to protect against ionizing radiation, a process known to 
produce •OH in excess (Vijayalaxmi et al., 1999; Sever et al., 
2004; Zhou et al., 2006).
Actually,  melatonin  scavenges  two  •OH  and,  in  the 
process,  it  is  converted  to  cyclic  3-hydroxymelatonin 
(3-OHMEL). This latter product was identified by mass 
spectral analysis and carbon and proton-nuclear magnetic 
resonance (Tan et al., 1998; 1999b). Small amounts of cyclic 
3-OHMEL are excreted in the urine (Ma et al., 2006); this 
also indicates that melatonin scavenges the •OH in vivo. 
Cyclic 3-OHMEL is also formed during the interaction of 
melatonin with ONOO– (Zhang et al., 1999; Peyrot et al., 
2002). Although cyclic 3-OHMEL is not commercially avail-
able, a method for its synthesis has been published (Sawicka 
et al., 2004) for those interested in using this molecule. 
Like  its  parent  molecule,  cyclic  3-OHMEL  is  also  a 
highly effective free radical scavenger and, in doing so, it 
is converted to N1-acetyl-N2-formyl-5-methoxykynuramine 
(AFMK) (Tan et al., 2000). This latter molecule is interest-
ing and its existence has been known for more than 30 years 
after its discovery in the rat brain, where it is enzymatically 
formed by indoleamine 2,3-dioxygenase from melatonin 
(Hirata et al., 1974). For decades this was thought to be 
the exclusive means of AFMK formation in vivo. It is now 
known, however, that it may be non-enzymatically pro-
duced when melatonin scavenges H2O2 (Tan et al., 2000), 
as well as when it interacts with O2
•– (Hardeland et al., 
1995), singlet oxygen (1O2) (de Almeida et al., 2003), or the 
ONOO– (Hardeland et al., 2003b). Finally, activated neutro-
phils and macrophages oxidize melatonin to AFMK (Silva et 
al., 2004). In plants as well as in animals, AFMK may be a 
major oxidation production of melatonin (Tan et al., 2007a). 
Collectively, the published findings suggest that AFMK is 
widely distributed in the animal and plant kingdoms. Like 
other melatonin catabolites, AFMK is found in the rat urine. 
Tan and colleagues (2007b) have speculated that AFMK 
may be a major derivative of melatonin.
AFMK has the ability to interact with the ABTS cation 
radical  as  well  as  with  ROS/RNS  to  form  N1-acetyl-5-
methoxykynurmaine (AMK) (Rosen et al., 2006). AMK is 
then both a secondary or tertiary metabolite of melatonin. 
When AMK interacts with the ABTS cation radical (Than 
et al., 2006) or with ONOO– (Guenther et al., 2005) it forms 
products that may also be ROS and RNS scavengers.
This sequential scavenging of toxic reactants by mela-
tonin and its metabolites is referred to as its antioxidative 
cascade and it is believed to be functional in vivo (Tan et al., 
2007a). In this scheme it has been estimated that a single 
molecule of melatonin may neutralize up to ten toxic reac-
tants. The oxidation reactions of melatonin as summarized 
in the foregoing paragraphs are summarized in Figure 1.
Supplementing the antioxidant capacity of melatonin is 
the ability of the indoleamine to promote the metabolism of 
toxic reactants to innocuous molecules. A number of anti-
oxidative enzymes are important in limiting the oxidative 
burden of cells and organisms. As noted above, the major 
enzymes in this category are CuZnSOD, MnSOD, catalase 
(CAT), GPx and GRd. The SOD isoforms dismutate O2
•– to 
H2O2 at different sites within the cell, i.e., CuZnSOD works 
in the cytosol while MnSOD is confined to mitochondria. 
While H2O2 is not very reactive it has a long half-life and 
can pass through cell membranes easily and, due to its 
conversion to the •OH via the Fenton reaction, it can cause 
molecular damage at sites distant from its place of origin. 
To prevent this from happening, it is catalytically removed 
from the cellular environment by GPx and CAT. When H2O2 
and/or other hydroperoxides are metabolized by GPx, GSH 
is likewise converted to its oxidized form, GSSG. Since it is 
important that a very high percentage of the glutathione in 
a cell be in the reduced form, GSSG is quickly metabolized 
back to GSH by the enzyme GRd. 
It has been known for more than a decade that the 
activities of the antioxidative enzymes mentioned above are 
heightened in the presence of exogenously administered, 
pharmacological doses of melatonin (Barlow-Walden et al., 
1995; Pablos et al., 1995). Furthermore, the physiological rise 
in circulating levels of melatonin at night reportedly enhances 
antioxidative enzyme activities (Pablos et al., 1998; Baydas 
et al., 2002). Besides seemingly inciting these enzymes, in 
some cases melatonin may merely protect these proteins 
from oxidative damage and thereby preserve their function.
Two recent reviews have considered the mechanisms 
involved in stimulation of antioxidative enzyme activities 
by melatonin (Rodriguez et al., 2004; Tomas-Zapico and 
Coto-Montes, 2005). While the direct free radical scaveng-
ing actions of melatonin described are obviously receptor-
independent, there is a general consensus, although the 
evidence  is  not  incontrovertible,  that  the  induction  of 
these enzymes by melatonin likely involves receptors. The 
proposed mechanisms include an interaction of melatonin 
with both membrane receptors and nuclear binding sites. 
The fact that melatonin (and its metabolites) functions in 140
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the direct scavenging of ROS/RNS as well as activating 
enzymes which remove these potentially toxic agents from 
the intracellular environment greatly increases its ability to 
ward off molecular damage. Whereas melatonin acts as a 
direct free-radical scavenger in every cell, its stimulation of 
antioxidative enzymes would be limited to cells that pos-
sess receptors for the indoleamine, if the theory presented 
by Rodriguez et al. (2004) and Tomas-Zapico and Coto-
Montes (2005) is valid. Considering the very wide spread 
distribution of at least the membrane melatonin receptors 
(Dubocovich and Markowska, 2005), and also presumably 
the nuclear binding sites (Pozo et al., 2003; Coto-Montes et 
al., 2003; Carrillo-Vico et al., 2005), this action of melatonin 
may also occur essentially throughout the organism.
NOS,  of  which  there  are  several  isoforms,  is  the 
rate-limiting  enzyme  in  the  production  of  the  gaseous 
neurotransmitter, NO. NO has both highly beneficial as 
well as negative consequences in organisms. As mentioned 
previously, this nitrogen-based reactant quickly couples 
with O2
•– to form ONOO– which is highly reactive and 
destructive. Thus, NOS is often considered a pro-oxidative 
enzyme and its inhibition leads to reduced oxidative dam-
age both at the cytosol and mitochondrial levels (Reiter 
et al., 2000; Acuna-Castroviejo et al., 2005). Melatonin 
reduces the activity of this enzyme when administered to 
experimental animals and at the same time it lessens free 
radical mutilation of essential molecules (Pozo et al., 1997; 
Benitez-King, 2006; Escames et al., 2004; Leon et al., 2006). 
In some cases, the inhibition of NOS by melatonin may 
contribute significantly to the total antioxidative capacity 
of the indoleamine particularly at the mitochondrial level 
(Acuna-Castroviejo et al., 2005).
As already noted, keeping GSH levels high within cells 
is an important means of preserving the morphological and 
functional activities of molecules which would otherwise be 
degraded by free radicals and associated reactive products. 
In 1999, Urata and colleagues specifically tested whether 
melatonin would preserve intracellular GSH concentrations 
by enhancing its synthesis. They found, in fact, that mela-
tonin stimulated the activity of the rate-limiting enzyme, 
γ-glutamylcysteine synthase (γ-GCS), in the production of 
this tripeptide antioxidant. Often, under elevated oxida-
tive stress conditions, melatonin preserves intracellular 
GSH levels. This is not necessarily related to the ability of 
melatonin to stimulate γ-GCS since the indoleamine could 
preferentially scavenger free radicals and thereby preserve 
basal intracellular GSH concentrations. The stimulation 
of γ-GCS, as originally described by Urata et al. (1999), has 
been confirmed (Winiarska et al., 2006).
One final aspect should be considered when melatonin’s 
ability to attenuate molecular impairment due to ROS/RNS 
is discussed. It is what Hardeland (2005) refers to as “radical 
avoidance”. Melatonin has stimulatory effects particularly 
on complexes I and IV of the mitochondrial ETC; as such, 
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Figure 1. Melatonin oxidation and the products formed. While the parent molecule, melatonin, is a potent free radical scavenger, so are its 
metabolites. This scheme is referred to as the scavenger cascade of melatonin. It has been calculated that one molecule of melatonin may scav-
enge up to ten ROS/RNS. The figure is a composite of the findings published by Hardeland and colleagues (1995; 2003a, 2003b) and Tan et al. 
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the number of electrons that leak from the complexes is 
reduced and free radical generation is attenuated. Limited 
free radical generation would result in less harm to neigh-
boring molecules.
This section briefly summarizes the multiple processes 
by which melatonin may restrict the destruction of mol-
ecules  and  organelles  normally  inflicted  by  ROS/RNS. 
Whereas these processes have all been documented in vivo, 
the significance of each in forestalling oxidative damage 
may be cell specific. 
Mitochondrial toxins: protection by melatonin
Several drugs have been identified which are classified as 
mitochondrial poisons, i.e., they interfere with the trans-
fer  of  electrons  through  the  ETC.  These  drugs  greatly 
exaggerate the escape of electrons into the mitochondrial 
intramembraneous space leading to a reduction of molecu-
lar oxygen and formation of radicals. Additionally, reduced 
oxidative phosphorylation precipitates a depletion of ATP 
(Beal, 1992). These changes cause elevated oxidative injury 
and an energy deficiency which, in the worst cases, leads 
to cellular and organismal death. The efficacy of melatonin 
in reducing the toxicity of some mitochondrial poisons has 
been examined.
Rotenone
Rotenone, a specific inhibitor of complex I of the mitochon-
drial ETC, causes the generation of an excessive number of 
free radicals. The damage inflicted by this drug is believed to 
be a consequence of the •OH (Saravanan et al., 2005; 2006). 
Rotenone has been used to induce a neurodegenerative 
condition in animals that is reminiscent of Parkinsonism in 
humans since its action in complex inhibition is considered 
specific to dopamine-containing neurons. The classic anti-
Parkinson drug, selegiline, protects against the neurodegen-
erative changes that are a consequence of rotenone due to its 
•OH scavenging actions (Saravanan et al., 2006).
Saravanan et al. (2007) stereotoxically infused rotenone 
(6µg in 1 µL) unilaterally into the right substantia nigra (SN) 
of rats to induce a condition of hemiparkinsonism and tested 
the effect of melatonin (10, 20 or 30 mg/kg, i.p., 30 minutes 
before surgery and at 12 hour intervals after surgery for 4 
days) in modulating the oxidative changes. At the termina-
tion of the study (5 days), measures of oxidative stress were 
compared in the infused and contralateral (non-rotenone 
treated) brain regions. On the rotenone-infused side of the 
brain nigral GSH levels were depressed by 49% while in the 
area of the terminals of the dopaminergic neurons (caudate 
nucleus, putamen; CNP), the reduction was 26%. Melatonin 
at all doses significantly reduced the loss of GSH in the SN 
while the two larger doses also limited the depletion of GSH 
in the CNP. When the rotenone-infused SN was compared 
with its counterpart on the contralateral side of the brain 
(neural tissue obtained by micropunch), the drug increased 
both  cytosolic  SOD  and  CAT  activities  in  the  drug-
damaged SN; the activities of both enzymes were further 
augmented after melatonin administration. The elevated 
enzyme activities after rotenone infusion were considered a 
compensatory response to the elevated oxidative stress. The 
additional rises induced by melatonin are consistent with 
its frequently-reported stimulation of antioxidative enzyme 
activities (Rodriguez et al., 2004; Tomas-Zapico and Coto-
Montes, 2005). That melatonin limited the loss of GSH in 
the rotenone-infused SN and associated CNP was explained 
by the fact that this indoleamine stimulates the rate limiting 
enzyme, γ-GCS, for the synthesis of this tripeptide antioxi-
dant (Urata et al., 1999; Winiarska et al., 2006).
In an important ancillary study published in the same 
report,  Saravanan  and  co-workers  (2007)  incubated 
neurally-derived submitochondrial particles (P2 fraction) 
with  rotenone  (100 µM),  salicylate  (0.7 mM)  and  differ-
ent  concentrations  of  melatonin  (0.1–1,000 µM)  for  30 
minutes. The formation of •OH adducts of salicylate, i.e., 
2,3-dihydroxybenzoic acid and 2,5-dihydroxybenzoic acid 
(2,3-DHBA and 2,5-DHBA, respectively) were estimated 
employing HPLC-electrochemistry. The addition of rotenone 
to the mitochondrial particles caused very large increases 
in 2,3-DHBA and 2,5-DHBA, indicative of highly elevated 
•OH generation, while melatonin significantly attenuated 
rotenone-mediated •OH formation by the mitochondria. 
The ability of melatonin to reduce •OH-salicylate adducts 
was not unexpected considering that melatonin, as well as 
its metabolites, are highly efficient scavengers of not only 
the •OH but any other radical or reactive species that may 
have been produced as a result of rotenone treatment (Tan et 
al., 1993; 2007b; Stasica et al., 1998, Hardeland, 2005).
Incubating isolated rat brain mitochondria with rotenone 
and Ca2+ induces marked oxidative damage to this organ-
elle. The addition of melatonin to the purified mitochondria 
reduced the oxidative mutilation caused by the combination 
of rotenone and Ca2+ (Sousa and Castillo, 2005). Also, the 
addition of a Ca2+ ionophore (A23187), strongly potentiated 
rotenone-mediated death of pheochromocytoma (PC12) 
cells, a response attenuated by melatonin. Furthermore, in 
the presence of melatonin, free radicals were not detected 
to be released from PC12 cells co-exposed to rotenone 
plus the Ca2+ ionophore. Since melatonin did not change 
the concentration of Ca2+ nor did it prevent the inhibitory 
effect of rotenone on mitochondrial complex I, the authors 
concluded that the beneficial effects of melatonin on the 
mitochondria were primarily related to the antioxidative 
and free radical scavenging capacity of the indoleamine 
(Sousa and Castillo, 2005).
The fruit fly, Drosophila melanogaster, has been devel-
oped as a model for several neurodegenerative diseases, 
including Parkinsonism (Feany and Bender, 2000; Auluck 
et al., 2002). This model was used to examine the ability 
of melatonin to change the response of flies to rotenone 
treatment (Coulom and Birman, 2004). The mitochondrial 
toxin was fed to flies in the food they consumed; likewise, 
melatonin was administered via this route. Within a week, 
rotenone-only fed flies exhibited characteristic motor defi-
cits and selective degeneration of the dopamine-containing 
neurons. When Drosophila were co-exposed to rotenone 
plus  melatonin  there  was  a  markedly  preserved  motor 
behavior of the flies and, furthermore, melatonin was clearly 142
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superior to L-dopa in improving the score of the flies in the 
geotaxis test. When the number of dopamine-containing 
cells in the nervous system was compared in rotenone-
treated flies with and without melatonin, it was obvious 
that the indoleamine had spared the dopaminergic neurons 
in many of the neuronal clusters from degeneration. In 
the rotenone-treated flies given melatonin, the number of 
dopaminergic neurons in some of the clusters was identical 
to those in non-treated control flies.
The difference between the relative efficacies of L-dopa 
and melatonin in reducing the toxicity of the mitochondrial 
complex I inhibitor in Drosophila is quite remarkable. While 
L-dopa attenuated some of the behavioral deficits associated 
with rotenone treatment, it failed to limit dopaminergic cell 
loss. Conversely, melatonin preserved normal behavior and 
reduced the destruction of the dopamine-containing neu-
rons. The authors surmised that the high free radical scav-
enging and antioxidative activity of melatonin accounted for 
its protective actions against rotenone toxicity, although yet 
undefined mechanisms could not be excluded. On the basis 
of the findings, the authors suggested the use of melatonin 
by humans to prevent the neural oxidative damage that 
accompanies Parkinson disease (Coulom and Birman, 2004).
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Roughly 30 years ago it was reported that young adults who 
unknowingly ingested MPTP developed severe neurological 
signs reminiscent of those seen in Parkinson disease (PD). It 
was immediately suspected that the drug caused damage to 
the dopaminergic cells of the substantia nigra which are the 
major neurons lost in individuals with idiopathic PD. When 
these individuals died and the brain was examined there 
was, in fact, a selective destruction of the mesencephalic 
dopamine-containing neurons. As tragic as these instances 
were, the identification of this destructive drug provided 
experimentalists with an agent that causes parkinson-like 
signs in animals. Use of MPTP has now become a model of 
examine the processes of PD as well as to investigate drugs 
that may modify the course of the disease.
When administered to animals, MPTP is taken up by 
astrocytes surrounding dopaminergic neurons and termi-
nals where it is metabolized to 1-methyl-4-phenylpyridinium 
(MPP+). The latter molecule is then released from the glial 
cells and is taken into dopaminergic nerves via the dop-
amine transporter. MPP+ interferes with complex I of the 
mitochondrial ETC; this leads to cellular energy depletion 
and eventually to the death of dopaminergic cells.
Within a rather short interval after discovery of mela-
tonin as an antioxidant, melatonin was used in an attempt 
to suppress the neural toxicity of MPTP. In this study, mice 
were injected with MPTP and were likewise given melatonin 
(Acuna-Castroviejo et al., 1997). Four hours later the brain 
of each mouse was recovered and the levels of lipid peroxi-
dation products were found to be increased in the striatum 
and hippocampus as a result of MPTP administration; these 
increments were not observed in the mice treated with mela-
tonin. More importantly, immunocytochemically-detected 
tyrosine hydroxylase activity in the dopaminergic nerve 
terminals in the striatum was lost as a result of the injection 
of MPTP; again this was prevented by melatonin. Although 
this study did not observe changes n the substantia nigra 
(likely due to the brief treatment period), the findings are 
consistent with a protective action of melatonin at the level 
of nigral dopaminergic neurons.
Shortly thereafter, a more thorough in vivo study that 
documented the ability of melatonin to limit damage to 
nigral dopaminergic neurons after MPP+ administration 
was published by Jin and co-workers (1998). Using rats, 
they showed that the rise in lipid peroxidation products in 
the substantia nigra as well as the reduction in neuronal 
tyrosine hydroxylase activity (the enzyme that determines 
dopamine synthesis) did not occur in MPP+-treated animals 
when melatonin was given concurrently. Both acutely or 
chronically administered melatonin attenuated the damage 
inflicted by MPP+. In mice as well, the toxicity of MPTP 
at the level of the substantia nigra is reduced by melatonin 
administration (Ortiz et al., 2001). The endpoints in this 
study were the degree of nuclear DNA fragmentation and 
neuronal apoptosis.
One of the most compelling reports regarding the ability 
of melatonin to deflect the toxicity of MPTP at the level of 
the substantia nigra was published by Antolin and colleagues 
(Antolin et al., 2002). To promote a gradual reduction in 
the loss of dopamine-containing neurons in the substantia 
nigra, this group treated mice with a low daily dose of 
MPTP for 35 days; in half of the animals each injection of 
the complex I inhibitor was preceded by co-administration 
of melatonin. MPTP by itself caused a dramatic reduction in 
the number of Nissl-stained neurons and immunoreactive 
tyrosine hydroxylase-positive cells in the substantia nigra. 
In the mice given melatonin in conjunction with MPTP, the 
measured parameters were essentially indistinguishable 
from those of the control mice (Figure 2). These findings, 
along with others published soon thereafter (Khaldy et al., 
2003; Chen et al., 2002) strongly support the idea that mela-
tonin protects against mitochondrial complex I dysregula-
tion induced by MPTP. That melatonin does not modify the 
conversion of MPTP to MPP+ was shown by the observation 
that the indoleamine did not alter the level of monoamine 
oxidase B (Thomas and Mohanokumar, 2004); this enzyme 
is responsible for the metabolism of MPTP to MPP+.
The most direct evidence that melatonin prevents the 
toxicity of MPTP/MPP+ at the level of the mitochondria 
was provided by Chen et al. (2005). This group measured 
mitochondrial DNA (mtDNA) damage as a result of MPTP 
administration to mice. They observed a rapid increase 
in  immunoreactive  8-hydroxy-2-deoxyguanosine,  a  reli-
able marker of DNA damage, in mtDNA of the substantia 
nigra. Melatonin pre-injection, in a dose-response manner, 
reduced the damage. Likewise, using cultured SH-SY5Y cells 
Chen et al. (2005) also found melatonin was protective of 
mtDNA against MPP+ toxicity and, moreover, they observed 
that MPP+ time-dependently elevated mitochondrial free 
radical generation and a reduction in the mitochondrial 
membrane potential over a 24 hour period. Furthermore, 72 
hours after MPP+ exposure, 49% of the cells had undergone 
apoptosis. When cells were co-incubated with a combina-
tion of MPP+ and melatonin, however, mitochondrial free 143
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radical generation was reduced, mitochondrial membrane 
potential did not collapse and cellular apoptosis was averted. 
3-Nitropropionic acid (3-NPA)
3-NPA is a plant fungal toxin which inactivates mitochon-
drial succinate dehydrogenase (Coles et al., 1979). Succinate 
dehydrogenase  (succinate-coenzyme  Q  reductase)  is  a 
key enzyme in complex II of the mitochondrial electron 
transport chain (Brandon et al., 2006). When 3-NPA is 
ingested by children who eat contaminated sugar cane, 
it causes basal ganglia lesions and marked dystonia as in 
Huntington’s disease (HD) (Ludolph et al., 1991). Similarly, 
when this toxin is either administered systemically or if 
it is stereotaxically injected directly into the striatum of 
rodents, the neuropathological and neurobehavioral signs 
are similar to those seen in individuals with HD (Borlongan 
et al., 1995). Being a mitochondrial toxin, 3-NPA probably 
depletes cellular energy levels, which is also a deficit that 
likely occurs in HD (Beal, 1992). 
To  simulate  HD,  Tunez  and  colleagues  (2004)  used 
the mycotoxin to induce oxidative stress in the striatum 
and cerebral cortex of rats and tested whether melatonin 
would  reduce  the  resulting  damage  caused  by  3-NPA. 
3-NPA  was  given  at  repeated  intraperitoneally  injected 
doses of 20 mg/kg BW (in dimethylsulfoxide) for 4 days 
while melatonin (1 mg/kg BW) was given via the same route 
(before, during and 4 days after mycotoxin administra-
tion). In both striatal and cerebrocortical synaptosomes, 
a 65–70% reduction in succinate dehydrogenase activity 
was measured in response to 3-NPA only; melatonin co-
administration returned the activity of this mitochondrial 
enzyme to near control levels. Associated with the loss in 
succinate dehydrogenase activity and a rise in free radical 
generation, the levels of lipid peroxidation products and 
protein carbonyls were elevated; both these consequences of 
mycotoxin administration were highly significantly reduced 
by melatonin. Whether melatonin actually prevented the 
drop in succinate dehydrogenase activity due to mycotoxin 
treatment or whether it merely restored enzyme activity 
after 3-NPA was discontinued could not be determined 
from this study.
A different approach was taken by Nam et al. (2005) who 
stereotoxically unilaterally injected 3-NPA into the striatum 
of rats while melatonin was given 30 minutes prior to and 60 
minutes after mycotoxin administration and daily for 3 days 
thereafter. The use of 2,3,5-triphenyltetrazolium chloride 
staining revealed large lesions with extensive neuronal loss 
in the striata that were injected with 3-NPA. Moreover, the 
3-NPA lesioned rats exhibited marked ipsilateral rotational 
behavior  in  response  to  apomorphine.  The  dopamine 
content of the damaged striata was also diminished while 
malondialdehyde (an index of the peroxidation of lipids) 
and oxidized protein levels were elevated in the area of the 
lesion. Melatonin given before and after the 3-NPA injection 
attenuated striatal neuronal loss, limited the degree of asym-
metric rotational movement, preserved dopamine levels and 
reduced the amount of lipid and protein oxidation.
While the results of only two studies have been published 
related to the use of melatonin to ameliorate 3-NPA toxicity, 
Figure 2. Tyrosine hydroxylase immunoreactivity of neurons in the 
substantia nigra of rats left untreated (top), given MPTP for 35 days 
(middle) or given MPTP + melatonin (bottom).  In the MPTP-only 
treated rats, the bulk of the dopaminergic neurons were lost, a change 
prevented by melatonin. From Antolin and co-workers (2002).144
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both reports showed conclusively that melatonin effectively 
counteracts the neuronal damage associated with succinate 
dehydrogenase poisoning. The findings are consistent with 
the idea that melatonin may have efficacy in the treatment 
of HD; this is supported by observations were melatonin was 
also found to be beneficial in another experimental model 
of this neurodegenerative condition, i.e., administration of 
quinolinic acid (Cabrera et al., 2000). 
Cyanide
Cyanide is a potent inhibitor of cellular respiration by acting 
on cytochrome oxidase thereby blocking electron transport. 
This results in reduced oxidative phosphorylation, oxygen 
utilization  and  elevated  free  radical  generation  in  the 
mitochondria.
Yamamoto and Tang (1996) performed a series of investi-
gations to determine whether melatonin would reverse some 
of the sequalae of cyanide. In a dose-dependent manner, the 
subcutaneous administration of potassium cyanide (6, 8, or 
9 mg/kg BW) to mice caused severe tonic/clonic seizures 
and neural lipid peroxidation. Melatonin does-dependently 
reduced both the seizure incidence and lipid peroxidation 
in the cyanide-treated mice. The effective dose of cyanide 
to cause seizures in 50% of the mice, i.e., ED50, was elevated 
when melatonin was co-administered while the frequency of 
death in half of the animals at 24 hours (LD50) was increased 
by melatonin treatment. The reduction in cyanide-mediated 
neural toxicity by melatonin was assumed to be related to 
the free radical scavenging activity of the indoleamine.
When  cultured  rat  cortical  neurons  were  exposed 
to  potassium  cyanide  over  a  range  of  concentrations 
(0.01–1.0 mM) lactate dehydrogenase efflux, indicative of 
cellular damage, into the culture medium was observed. 
Melatonin significantly reduced escape of the enzyme from 
the neurons and preserved their morphology (Yamamoto 
and Tang, 1998). These researchers also showed, both in 
vitro and in vivo, that the damage to rat mtDNA by cyanide 
is also abolished by melatonin co-treatment (Yamamoto and 
Mohanan, 2002). The authors assumed that the mitochon-
drial dysfunction caused by cyanide initiated essentially 
uncontrolled free radical generation leading to oxidative 
mutilation of the neighboring mtDNA. This being the case, 
melatonin’s ability to limit disfiguration of mtDNA was very 
likely a result of the high efficiency of the indoleamine as a 
scavenger of reactive oxygen and reactive nitrogen species. 
Apoptosis: prevention by melatonin
One definitive endpoint of mitochondrial free radical gen-
eration is cellular apoptosis. Antioxidants that reduce the 
production of ROS/RNS at the mitochondrial level would 
be expected to limit cellular death. Using appropriate fluo-
rescent probes, free radical production in mitochondria can 
be visualized along with many of the downstream events 
which culminate in the demise of the cell. With regard to 
melatonin’s ability to act in mitochondria to alter the rate of 
free radical production, the most thorough studies are those 
of Jou and colleagues (Jou et al., 2002, 2004, 2007).
To initially observe intramitochondrial ROS, the fluo-
rescent dye dihydrorhodamine-123, was used in astrocytes 
exposed to visible laser radiation. Using time-lapse confocal 
imaging of ROS production after subjecting astrocytes to 
laser irradiation, Jou et al. (2002) documented the dramatic 
increase in ROS over a 20 minutes period. The bulk of these 
reactants was clearly created within mitochondria. By imag-
ing the changes at 30 sec intervals for 20 minutes, the ROS 
were seen to accumulate rather slowly over the first 4 min-
utes of laser exposure with a much more rapid increase over 
the last 15 minutes. Concurrent phase contrast microscopy 
demonstrated the presence of other apoptosis-related cel-
lular changes, e.g., cytoplasmic blebbing, nuclear condensa-
tion, etc. Moreover, melatonin and another antioxidant, 
vitamin  E,  largely  attenuated  laser  irradiation-induced 
mitochondrial ROS formation and prevented apoptosis. In 
their most recent investigation, Jou and co-workers (2007) 
documented that, even in cells that have a common deletion 
of mitochondrial DNA and therefore generate an excess of 
free radicals, melatonin is still capable of reducing oxidative 
damage and preventing apoptosis.
In a second, more complete study, this group examined 
in detail many aspects of apoptosis and showed that mela-
tonin also prevented death of cells caused by the oxidizing 
agent, H2O2 (Jou et al., 2004). With the aid of non-invasive 
mitochondrial-targeted fluorescent probes and time-lapse 
conventional, confocal, and multiphoton fluorescent imag-
ing microscopy, the authors were able to show that melatonin 
effectively prevented endogenously-applied H2O2-induced 
mitochondrial swelling and apoptotic cell death. Moreover, 
melatonin reduced plasma membrane exposure of phosphati-
dyl serine, mitochondrial transition pore (MTP) opening, 
cytochrome c release, positive YOPRO-1 staining of the early 
apoptotic nuclei and DNA laddering. Besides inhibiting the 
apoptotic events initiated in astrocytes by H2O2, melatonin 
also reduced free radical formation and other degenerative 
cellular processes that resulted from the exposure of cells to 
either tert-butyl hydroperoxide or cumene hydroperoxide. 
Additionally, the protective effect of melatonin against these 
damaging agents was better than that provided by vitamin 
E (Jou et al., 2004). Figure 3 summarizes the processes 
involved in melatonin’s actions in preventing free radical-
mediated,  mitochondrial-dependent  cellular  apoptosis.
The greater efficacy of melatonin in reducing observable 
free radical generation and apoptotic processes than vita-
min E is a common observation. A number of studies have 
compared melatonin with classic antioxidants, e.g., gluta-
thione, mannitol, vitamin C, vitamin E, etc., and invariably 
melatonin performs in a superior manner (Sofic et al., 2005; 
Qi et al., 2000; Martin et al., 2000).
According to Jou and colleagues (2004) the opening of 
the MTP follows free radical damage that accompanies 
oxidant  exposure.  However,  other  studies  suggest  that 
melatonin additionally, may have direct effects on the pore 
which prevent its opening and the escape of cytochrome c 
(Andrabi et al., 2004). 
Besides reducing free radical-mediated, mitochondrial-
dependent apoptosis, a process that does not require an 
interaction of melatonin with a receptor, melatonin may 145
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also  have  a  receptor-mediated  means  of  reducing  the 
likelihood of apoptosis. Kilic et al. (2005a) examined the 
activation of a cytosolic signaling pathway after transient 
focal  neural  ischemia,  which  induces  massive  neuronal 
apoptosis, in mice. They used Western blots to analyze the 
phosphorylation of AKt, mitogen-activated protein (MAP) 
kinase/extracellular-regulated kinase (ERK)-1/2 and Jun 
kinase (JUN)-1/2 since they are crucial factors in reducing 
cellular death. On the basis of their results, however, Kilic 
and  co-workers  (2005a)  concluded  that  phosphorylated 
ERK-1/2 and phosphorylated JNK-1/2 were not involved in 
melatonin’s protection against neuronal loss after ischemia/
reperfusion injury to the brain. On the other hand, melato-
nin markedly upregulated phosphorylated AKt suggesting 
that  the  phosphoinositol-3  kinase/Akt  pathway  (PI-3K) 
is involved in mediating melatonin’s protective actions in 
reducing neuronal loss due to apoptosis.
A follow-up study by the same group that melatonin 
acts to preserve the function of the PI-3 K/Akt pathway 
(Kilic et al., 2005b); this pathway has an inhibitory effect 
on mitochondrial injury and caspase activation (Yoshimoto 
et al., 2001; Friguls et al., 2002). As a result of the activation 
of the PI-3K pathway, phosphorylated Akt binds to Bad, a 
pro-apoptotic member of the Bcl-2 family; this impedes 
the translocation of Bad to the mitochondria. When phos-
phorylated Akt levels are lowered, Bad heterodimerizes 
with anti-apoptotic Bcl-2 members thereby reducing their 
efficacy in executing their cytoprotective actions (Abe et al., 
H2O2
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Figure 3. This figure summarizes the findings as uncovered by Jou et al. (2004).  By effectively scavenging reactive oxygen species generated 
within mitochondria, melatonin prevents the collapse of the mitochondrial membrane potential, opening of the mitochondrial transition pore 
(MTP) and the downstream events that lead to cellular apoptosis. Additionally, melatonin may have direct actions on the mitochondrial transition 
pore that are unrelated to its scavenging activity.146
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2004). Thus, melatonin’s anti-apoptotic effects may be, at 
least in part, a result of its ability to preserve the activity of 
the PI-3K/Akt pathway. This explanation could also be used 
to define the findings of You et al. (2006) who reported the 
up-regulation of BcL-XL and the reduction in cytochrome 
c release from mitochondria by melatonin in the damaged 
newborn rat brain. 
Concluding remarks
Mitochondria are the site of a large percentage of free radi-
cals and related toxicants that are generated in cells. These 
reactive products cause damage to essential mitochondrial 
molecules which result in opening of the mitochondrial 
transition pore, release of cytochrome c and activation 
of the down stream events that culminate in free radical-
mediated, mitochondrial-dependent apoptosis.
Since melatonin was discovered to be an indirect anti-
oxidant and direct efficient free radical scavenger, its ability 
to reduce oxidative stress and to curtail cellular apoptosis 
has been repeatedly documented. It has also been shown 
that part of melatonin’s ability to quell the oxidation of key 
molecules stems from its conversion to metabolites, i.e., 
cyclic 3-OHMEL, AFMK and AMK when it incapacitates 
free radicals and their related products.
The ability of melatonin to protect against oxygen- and 
nitrogen-based reactants is obvious in situations where tox-
ins that inhibit the mitochondrial electron transport com-
plexes are used. The mitochondrial poisons cause electron 
leakage with the resultant formation of large numbers of 
free radicals and consequentially molecular damage. This 
mutilation is inhibited by melatonin and its metabolites.
While melatonin readily resists mitochondrial oxidative 
damage and cellular apoptosis, there are many unanswered 
questions remaining. Some of the most noteworthy relate 
to the intramitochondrial concentrations of melatonin, the 
precise location of the indoleamine in relation to the com-
plexes of the ETC, is it melatonin or a melatonin derivative 
that is the active agent in mitochondria and a definitive 
explanation for its high efficacy in preventing mitochondrial 
and cellular free radical-mediated destruction. Melatonin’s 
very low toxicity combined with its high efficacy, however, 
portends its use in clinical medicine to treat conditions 
that are associated with elevated free radical damage, e.g., 
septic shock (Gitto et al., 2001), certain neurodegenerative 
conditions (Pappolla et al., 2003; Ishido, 2007), ischemia/
reperfusion injury (Reiter et al., 2005), ionizing radiation 
(Vijayalaxmi et al., 2004; Manda et al., 2007), and toxin 
(Xu et al., 2007; Matsura et al., 2006) and heavy metal (Qi et 
al., 2002; El-Sokkary et al., 2003) exposure, among others.
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